Published in J Am Coll Surg on February 11, 2015
Therapeutic Approach to Cystic Neoplasms of the Pancreas. Surg Oncol Clin N Am (2016) 0.84
KRAS, GNAS, and RNF43 mutations in intraductal papillary mucinous neoplasm of the pancreas: a meta-analysis. Springerplus (2016) 0.81
Targeted DNA Sequencing Reveals Patterns of Local Progression in the Pancreatic Remnant Following Resection of Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas. Ann Surg (2016) 0.80
The oncocytic subtype is genetically distinct from other pancreatic intraductal papillary mucinous neoplasm subtypes. Mod Pathol (2016) 0.79
Distinct pathways of pathogenesis of intraductal oncocytic papillary neoplasms and intraductal papillary mucinous neoplasms of the pancreas. Virchows Arch (2016) 0.76
Do molecular tests really differentiate malignant IPMNS from benign? Endosc Int Open (2016) 0.75
Pancreatic Cancer Chemoprevention Translational Workshop: Meeting Report. Pancreas (2016) 0.75
Next-Generation Sequencing in Oncology: Genetic Diagnosis, Risk Prediction and Cancer Classification. Int J Mol Sci (2017) 0.75
Endoscopic ultrasound-guided fine-needle aspiration plus KRAS and GNAS mutation in malignant intraductal papillary mucinous neoplasm of the pancreas. Endosc Int Open (2016) 0.75
Diversity of Precursor Lesions For Pancreatic Cancer: The Genetics and Biology of Intraductal Papillary Mucinous Neoplasm. Clin Transl Gastroenterol (2017) 0.75
Insights into the Pathogenesis of Pancreatic Cystic Neoplasms. Dig Dis Sci (2017) 0.75
A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet (2011) 59.36
Integrative genomics viewer. Nat Biotechnol (2011) 42.83
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol (2013) 16.13
International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology (2012) 7.22
High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov (2011) 5.30
Intraductal papillary mucinous neoplasms of the pancreas: an updated experience. Ann Surg (2004) 5.12
Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci Transl Med (2011) 5.03
Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. Proc Natl Acad Sci U S A (2011) 3.51
Classification of types of intraductal papillary-mucinous neoplasm of the pancreas: a consensus study. Virchows Arch (2005) 2.76
Intraductal papillary mucinous neoplasms of the pancreas: an analysis of clinicopathologic features and outcome. Ann Surg (2004) 2.62
Whole-exome sequencing uncovers frequent GNAS mutations in intraductal papillary mucinous neoplasms of the pancreas. Sci Rep (2011) 2.09
Pathologically and biologically distinct types of epithelium in intraductal papillary mucinous neoplasms: delineation of an "intestinal" pathway of carcinogenesis in the pancreas. Am J Surg Pathol (2004) 1.96
Precursors to pancreatic cancer. Gastroenterol Clin North Am (2007) 1.75
Detecting somatic genetic alterations in tumor specimens by exon capture and massively parallel sequencing. J Vis Exp (2013) 1.68
Activating GNAS mutations in parosteal osteosarcoma. Am J Surg Pathol (2014) 1.47
Thyroid carcinoma in the McCune-Albright syndrome: contributory role of activating Gs alpha mutations. J Clin Endocrinol Metab (2003) 1.36
Targeted next-generation sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the pancreas. J Pathol (2014) 1.33
Activating mutations of Gsalpha in kidney cancer. J Urol (2006) 1.31
GNAS-activating mutations define a rare subgroup of inflammatory liver tumors characterized by STAT3 activation. J Hepatol (2011) 1.25
Frequent activating GNAS mutations in villous adenoma of the colorectum. J Pathol (2012) 1.22
Frequent GNAS and KRAS mutations in pyloric gland adenoma of the stomach and duodenum. J Pathol (2013) 1.22
Clinicopathological correlates of activating GNAS mutations in intraductal papillary mucinous neoplasm (IPMN) of the pancreas. Ann Surg Oncol (2013) 1.11
Invasive carcinoma arising in intraductal papillary mucinous neoplasms of the pancreas: a matched control study with conventional pancreatic ductal adenocarcinoma. Ann Surg (2011) 1.07
Histologic, immunohistochemical, and molecular classification of 52 IPMNs of the pancreas. Appl Immunohistochem Mol Morphol (2009) 0.99
GNAS and KRAS mutations are common in intraductal papillary neoplasms of the bile duct. PLoS One (2013) 0.93
GNAS sequencing identifies IPMN-specific mutations in a subgroup of diminutive pancreatic cysts referred to as "incipient IPMNs". Am J Surg Pathol (2014) 0.92
A GNAS mutation found in pancreatic intraductal papillary mucinous neoplasms induces drastic alterations of gene expression profiles with upregulation of mucin genes. PLoS One (2014) 0.88
Residual disease predicts outcomes after definitive resection for incidental gallbladder cancer. J Am Coll Surg (2014) 1.48
Minimally-invasive vs open pancreaticoduodenectomy: systematic review and meta-analysis. J Am Coll Surg (2013) 1.09
Distal pancreatectomy: a single institution's experience in open, laparoscopic, and robotic approaches. J Am Coll Surg (2014) 0.95
Deformation correction for image-guided liver surgery: An intraoperative assessment of fidelity. Surgery (2017) 0.75